Avacta is a healthcare group developing innovative cancer drugs and powerful in vitro diagnostics to improve human health and well-being. Avacta’s Therapeutics division, based in White City, London, U.K. develops novel cancer therapies using its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Using the Affimer® platform Avacta is focusing on immunotherapies in the fight against cancer. Avacta’s Diagnostics division, based in Wetherby, UK., is using the Affimer® platform with the aim of developing market leading diagnostic products.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.